Article Type
Original Research
Published
In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.
Original Research
In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.
Original Research
The aim of this survey was to investigate satisfaction with, preference for, and adherence to lanthanum carbonate oral powder in patients with end-stage renal disease (ESRD). The authors concluded that patients with ESRD report increased satisfaction with and preference for lanthanum carbonate powder over other formulations, suggesting that lanthanum carbonate powder is more convenient and easier to use than other formulations.
Original Research
In this analysis the authors used health economics assessment data collected during the QUAlity of LIfe with AbiliFY Maintena (QUALIFY) study, a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months. The authors concluded that the analysis of data from stabilized patients with schizophrenia in the QUALIFY study indicated that AOM 400 is associated with lower health-care costs and greater effectiveness compared with PP and thus represents the economically dominant strategy.
Review
This paper summarizes the results from the ground-breaking EMPA-REG OUTCOME study and discusses their significance and clinical implications.
Original Research
In this article the authors aim to harmonise the diagnosis of seasonal influenza and the approach of European general practitioners to vaccination in order to better identify influenza outbreaks and achieve a target vaccination rate of 75% throughout Europe.